by Portfolio Grader | November 13, 2013 11:00 am
This week, seven Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Inovio Pharmaceuticals, Inc.’s (AMEX:INO) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Inovio Biomedical Corporation is a Delaware corporation, organized in 2001. The Company is engaged in the development of preventive and therapeutic DNA vaccines for cancers and infectious diseases using its novel electroporation DNA delivery technology. Electroporation uses brief, controlled electrical pulses to increase cellular uptake of useful biopharmaceuticals. In Portfolio Grader’s specific subcategory of Sales Growth, INO also gets an A. For more information, get Portfolio Grader’s complete analysis of INO stock.
This week, ARIAD Pharmaceuticals, Inc.’s (NASDAQ:ARIA) ratings are up from a C last week to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) earns a B this week, jumping up from last week’s grade of C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Incorporated (NASDAQ:INSM) improves from a C to a B rating this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
This week, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) pushes up from a C to a B rating. BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. For more information, get Portfolio Grader’s complete analysis of BCRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/11/7-biotechnology-stocks-to-buy-now-ino-aria-nbix/
Short URL: http://invstplc.com/1fu6Kxx